NEW YORK (GenomeWeb) – Intellia Therapeutics, a company developing CRISPR/Cas9-based treatments, has leased 65,000 square feet of space near the Massachusetts Institute of Technology in Cambridge, Massachusetts. The expansion comes as it plans to launch a new division that will focus on research to develop ex vivo therapies such as cell editing.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.